Generic User Fee Negotiations May Be Falling Behind Schedule
This article was originally published in The Pink Sheet Daily
FDA and industry look to speed up the talks with GDUFA financial issues still to come.
You may also be interested in...
Negotiations for generic drug user fee reauthorization open with FDA saying it doesn't want a large number of small tweaks that will increase program complexity.
Concept could help sponsors who reach approvability but must wait several years before reference product exclusivity expires.
Not only did White House and other officials support the recommendation, but also made clear they had no advance notice of it.